News

Study of 400,000 pediatric records shows vaccine’s effectiveness in preventing Long COVID during Delta and Omicron waves.

Since its detection in early 2024, H5N1 has spread to dairy cows, poultry, and wild birds. Political factors, including leadership changes at the Centers for Disease Control and Prevention and cuts to public health resources, have worsened the situation, leading to a weakened response.

Universal hepatitis C screening updates have influenced testing numbers, and resulted in a gradual increase for all women with a pronounced increase in pregnant women.

This week, the CDC ACIP's endorsement of meningococcal, RSV, and chikungunya vaccines, the need to expand automated CD4 testing for improved HIV/AIDS care, and more.

With valid phase 2 results, hydronidone could pave the way for first antifibrotic treatment in chronic liver disease.

Matthew Hepburn, MD, executive vice president of research and development at Panther Life Sciences, discusses the technology and its potential usage.

Six hundred thirty-seven cases in England, 4514 US clinical cases in 2023, and only 3 late‑stage antifungal drugs reveal surveillance and treatment gaps.

This case represents the second reported human infection with avian influenza A(H5) in Mexico, and the first confirmed case of influenza A(H5N1) in the country. The patient was a child who died from respiratory complications.

Sabrina Absalon, PhD's research uncovers the essential role of PfAnchor in apicoplast division, opening avenues for targeted antimalarial therapies.

A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).

Yael David, PhD, discusses how cccDNA nucleosome positioning drives HBV transcription and how CBL137 disrupts this process to block infection.

ACIP provides recommendations on meningococcal vaccines, RSV vaccination for at-risk adults, and chikungunya vaccines for travelers and laboratory workers, while also addressing safety concerns and potential expansions of use for each.

The Centers for Disease Control and Prevention (CDC) says there are now 7 outbreaks.

Precision BioSciences received the designation for its gene editing therapy, PBGENE-HBV, developed to eliminate the root cause of chronic hepatitis B virus (HBV).

Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.

In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.

To meet ambitious targets for ending the HIV/AIDS epidemic, governments must unite in a global effort to improve access to CD4 testing.

CDC maintains low public health risk despite more cases, the first reported death, and accelerated vaccine development to enhance pandemic preparedness.

MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.

Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of
Clinical Microbiology and Infectious Diseases.

A surge in invasive group A Streptococcal (IGAS) infections in children marked by more virulent strains followed a reduction in cases coinciding with protective measures for the pandemic.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Carl Schmid, executive director, HIV+Hepatitis Policy Institute, speaks to these closings.

Ross M Boyce, MD, MSc, discusses the diagnostic challenges and the need for greater awareness of tick-borne illnesses in the US, considering their potential severity.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Jane E. Sykes, BVSc (Hons), PhD, MPH, MBA, discussed how her study revealed a wider geographic distribution of valley fever, highlighting the need for improved human surveillance.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.

During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.

Investigational sa-mRNA vaccine advances to phase 1 trials for pandemic preparedness.